Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma

Michele Miraglia Del Giudice, Cristiana Indolfi, Michele Capasso, Nunzia Maiello, Fabio Decimo, Giorgio Ciprandi, Michele Miraglia Del Giudice, Cristiana Indolfi, Michele Capasso, Nunzia Maiello, Fabio Decimo, Giorgio Ciprandi

Abstract

Background: Allergic rhinitis (AR) and allergic asthma are caused by an IgE-mediated inflammatory reaction. Probiotics may exert anti-inflammatory and immune-modulatory activity. Thus, this study aimed at investigating whether a Bifidobacteria mixture could be able to relieve nasal symptoms, and affect quality of life (QoL) in children with AR and intermittent asthma due to Parietaria allergy.

Materials and methods: The present study was conducted as placebo-controlled, double-blinded, and randomized. Globally, 40 children (18 males; mean age 9 ± 2.2 years) were enrolled. They were treated with probiotics or placebo: 1 sachet/day for 4 weeks. AR symptoms, and QoL were assessed at baseline and after treatment. Use of rescue medications, such as cetirizine syrup and salbutamol spray, was also permitted and recorded.

Results: Children treated with probiotic mixture achieved a significant improvement of symptoms (p < 0.005), and QoL ((p < 0.001). Placebo group had worsening of symptoms (p < 0.005) and QoL (p < 0.001). The use of rescue medications was overlapping in the two groups. The intergroup analysis showed that probiotic mixture was significantly superior than placebo for all parameters.

Conclusions: The current study demonstrated that a Bifidobacteria mixture was able of significantly improving AR symptoms and QoL in children with pollen-induced AR and intermittent asthma.

Clinical trial registration: ClinicalTrials.gov ID NCT02807064 .

Keywords: Allergic rhinitis; Bifidobacteria; Children; Intermittent asthma; Probiotic; Quality of life.

Figures

Fig. 1
Fig. 1
Total symptom scores in patients treated with Placebo (Group A) or Bifidobacteria mixture (Group B) at baseline (T0) and after treatement (T1). Data are expressed as medians, IQR, and standard deviations
Fig. 2
Fig. 2
QoL = practical problems item in patients treated with Placebo (Group A) or Bifidobacteria mixture (Group B) at baseline (T0) and after treatement (T1). Data are expressed as medians, IQR, and standard deviations

References

    1. Settipane RA, Schwindt C. Chapter 15: Allergic rhinitis. Am J Rhinol Allergy. 2013;27(Suppl 1):S52–5. doi: 10.2500/ajra.2013.27.3928.
    1. Dondi A, Tripodi S, Panetta V, Asero R, DiRienzo-Businco A, Bianchi A, et al. Italian Pediatric Allergy Network (I-PAN). Pollen-induced allergic rhinitis in 1360 Italian children: comorbidities and determinants of severity. Pediatr Allergy Immunol. 2013;24:742–51. doi: 10.1111/pai.12136.
    1. Global Initiative for Asthma. GINA guidelines. Global strategy for Asthma Management and Prevention. Available at: . Accessed July 2016.
    1. Alroqi FJ, Chatila TA. T Regulatory Cell Biology in Health and Disease. Curr Allergy Asthma Rep. 2016;16:27. doi: 10.1007/s11882-016-0606-9.
    1. Miraglia Del Giudice M, Marseglia A, Leonardi S, La Rosa M, Salpietro C, et al. Allergic rhinitis and quality of life in children. Int J Immunopathol Pharmacol. 2011;24:25–28. doi: 10.1177/03946320110240S406.
    1. Barberi S, Bernardo L, Bellasio M, Ferrara F, Tosi S, Ciprandi G. Nose-bronchi link: does an asthma march exist? J Biol Regul Homeost Agents. 2015;29:941–3.
    1. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;18:1259–60. doi: 10.1136/bmj.299.6710.1259.
    1. Liu AH. Revisiting the hygiene hypothesis for allergy and asthma. J Allergy Clin Immunol. 2015;136:860–5. doi: 10.1016/j.jaci.2015.08.012.
    1. Gilliland SE, Morelli L, Reid G. Proceedings from the FAO/WHO Expert Consultation. Cordoba, Argentina: FAO. Food and Nutrition. 2001. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria.
    1. Vliagoftis H, Kouranos VS, Betsi GI, Falagas ME. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Allergy Asthma Immunol. 2008;101:570–9. doi: 10.1016/S1081-1206(10)60219-0.
    1. Lin W-Y, Lin-Shien F, Lin H-K, Shen C-Y, Chen Y-J. Evaluation of the Effect of Lactobacillus paracasei in Children with Perennial Allergic Rhinitis: A 12-week, Double-blind, Randomized, Placebo-controlled Study. Pediatr Neonatol. 2013;20:S1875–9572.
    1. West CE. Probiotics for allergy prevention. Benef Microbes. 2016;7:171–9. doi: 10.3920/BM2015.0073.
    1. Zajac AE, Adams AS, Turner JH. A systematic review and meta-analysis of probiotics for the treatment of allergic rhinitis. Int Forum Allergy Rhinol. 2015;5:524–32. doi: 10.1002/alr.21492.
    1. Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res. 2007;62:215–20. doi: 10.1203/PDR.0b013e3180a76d94.
    1. Miraglia del Giudice M, Leonardi S, Ciprandi G, Galdo F, Gubitosi A, La Rosa M, et al. Probiotics in childhood: allergic illness and respiratory infections. J Clin Gastroenterol. 2012;46:S69–72. doi: 10.1097/MCG.0b013e318266fea7.
    1. Das RR, Singh M, Shafiq N. Probiotics in treatment of allergic rhinitis. World Allergy Organ J. 2010;3:239–44. doi: 10.1097/WOX.0b013e3181f234d4.
    1. Lue KH, Sun HL, Lu KH, Ku MS, Sheu JN, Chan CH, et al. A trial of adding Lactobacillus johnsonii EM1 to levocetirizine for treatment of perennial allergic rhinitis in children aged 7e12 years. Int J Pediatr Otorhinolaryngol. 2012;76:994–1001. doi: 10.1016/j.ijporl.2012.03.018.
    1. Chen YS, Jan RL, Lin YL, Chen HH, Wang JY. Randomized placebo-controlled trial of Lactobacillus on asthmatic children with allergic rhinitis. Pediatr Pulmonol. 2010;45:1111–20. doi: 10.1002/ppul.21296.
    1. Miraglia Del Giudice M, Maiello N, Decimo F, Fusco N, D’ Agostino B, Sullo N, et al. Airways allergic inflammation and L. reuterii treatment in asthmatic children. J Biol Regul Homeost Agents. 2012;26:35–40.
    1. Bin-Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147:192–6. doi: 10.1016/j.jpeds.2005.03.054.
    1. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005;115:1–4. doi: 10.1542/peds.2004-1463.
    1. Akiyama K, Shimada M, Ishizeki S, Takigawa I, Imura S, Yamauchi K, et al. Effects of oral administration of Bifidobacterium on the change of intestinal microflora induced by antibiotic therapy in extremely low birth weight infants. J Jpn Pediatr Soc. 1995;99:1436–41.
    1. Satoh Y, Shinohara K, Umezaki H, Shoji H, Satoh H, Ohtsuka Y, et al. Bifidobacteria prevents necrotizing enterocolitis and infection in preterm infants. Int J Probiotics Prebiotics. 2007;2:149–54.
    1. Hattori K, Yamamoto A, Sasai M, Taniuchi S, Kojima T, Kobayashi Y, et al. Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis. Jpn J Allergol. 2003;52:20–30.
    1. Namba K, Hatano M, Yaeshima T, Takase M, Suzuki K. Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly. Biosci Biotechnol Biochem. 2010;74:939–45. doi: 10.1271/bbb.90749.
    1. Xiao JZ, Kondo S, Yanagisawa N, Takahashi N, Odamaki T, Iwabuchi N, et al. Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo- controlled trial. Clin Exp Allergy. 2006;36:1425–35. doi: 10.1111/j.1365-2222.2006.02575.x.
    1. Yaeshima T, Fujisawa T, Mitsuoka T. Bifidobacterium species ex pressing phenotypical similarity to Bifidobacterium adolescentis isolated from the feces of human adults. Bifidobact Microflora. 1992;11:25–32. doi: 10.12938/bifidus1982.11.1_25.
    1. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999;69:S1035–45.
    1. Toscano M, De Vecchi E, Gabrieli A, Zuccotti GV, Drago L. Probiotic characteristics and in vitro compatibility of a combination of bifidobacterium breve M-16V, Bifidobacterium longum subsp. Infantis M-63 and Bifidobacterium longum subsp. Longum BB536. Ann Microbiol. 2015;65:1079–86. doi: 10.1007/s13213-014-0953-5.
    1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen) Allergy. 2008;63(Suppl. 86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x.
    1. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the Mini Rhinoconjunctivitis quality of life questionnaire. Clin Exp Allergy. 2000;30:132–40. doi: 10.1046/j.1365-2222.2000.00668.x.
    1. Frei R, Akdis M, O’Mahony L. Prebiotics, probiotics, synbiotocs, and the immune system: experimental data and clinical evidence. Curr Opin Gastroenterol. 2015;31:153–8. doi: 10.1097/MOG.0000000000000151.
    1. Strisciuglio C, Miele E, Giugliano FP, Vitale S, Andreozzi M, Vitale A, et al. Bifidobacteria enhance antigen sampling and processing by dendritic cells in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1491–8. doi: 10.1097/MIB.0000000000000389.
    1. Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, De Giovanni D, Campanozzi A, et al. A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Clin Gastroenterol. 2016 (in press).
    1. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections (Review) Cochrane Database Syst Rev. 2015;2:CD006895.
    1. Foligne E, Nutten S, Grangette C, et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol. 2007;13:236–43. doi: 10.3748/wjg.v13.i2.236.
    1. Lammers KM, Brigidi P, Vitali B, et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol. 2003;38:165–72. doi: 10.1016/S0928-8244(03)00144-5.
    1. Zoumpopoulou G, Tsakalidou E, Dewulf J, et al. Differential crosstalk between epithelial cells, dendritic cells and bacteria. Int J Food Micro. 2009;131:40–51. doi: 10.1016/j.ijfoodmicro.2008.12.037.
    1. Ouwehand AC, Nermes M, Collado MC, et al. Specific probiotics alleviate allergic rhinitis during the birch pollen season. World J Gastroenterol. 2009;15:3261–8. doi: 10.3748/wjg.15.3261.
    1. Castellazzi AM, Valsecchi C, Caimmi S, Licari A, Marseglia A, Leoni MC, et al. Probiotics and food allergy. Ital J Pediatr. 2013;29(39):47. doi: 10.1186/1824-7288-39-47.
    1. Lionetti E, Francavilla R, Castellazzi AM, Arrigo T, Labò E, Leonardi S, et al. Probiotics and Helicobacter pylori infection in children. J Biol Regul Homeost Agents. 2012;26(1 Suppl):S69–76.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren